Inventor
ALLERSDORFER ANDREA
DE26 patents
⚠️ This page may combine multiple inventors who share the name “ALLERSDORFER ANDREA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
PIERIS PHARMACEUTICALS GMBH
18 patentsUS10526382B2Jan 7, 2020
Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof
PIERIS PHARMACEUTICALS GMBH6 citations82
US10273275B2Apr 30, 2019
Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
PIERIS PHARMACEUTICALS GMBH10 citations82
US11345728B2May 31, 2022
Specific-binding polypeptides and uses thereof
PIERIS PHARMACEUTICALS GMBH2 citations72
US11261221B2Mar 1, 2022
Proteins specific for CD137
PIERIS PHARMACEUTICALS GMBH2 citations72
US10774119B2Sep 15, 2020
Specific-binding polypeptides and uses thereof
PIERIS PHARMACEUTICALS GMBH3 citations72
US10526384B2Jan 7, 2020
Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
PIERIS PHARMACEUTICALS GMBH5 citations72
US10501510B2Dec 10, 2019
Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof
PIERIS PHARMACEUTICALS GMBH4 citations71
US10400016B2Sep 3, 2019
Proteins specific for calcitonin gene-related peptide
PIERIS PHARMACEUTICALS GMBH4 citations71
US9950034B2Apr 24, 2018
Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
PIERIS PHARMACEUTICALS GMBH3 citations71
US12195503B2Jan 14, 2025
Proteins specific for CD137
PIERIS PHARMACEUTICALS GMBH0 citations62
US11034738B2Jun 15, 2021
Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)
PIERIS PHARMACEUTICALS GMBH0 citations61
US11034737B2Jun 15, 2021
Proteins specific for calcitonin gene-related peptide
PIERIS PHARMACEUTICALS GMBH1 citations61
US10927156B2Feb 23, 2021
Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune response
PIERIS PHARMACEUTICALS GMBH1 citations61
US11773147B2Oct 3, 2023
Lipocalin muteins with binding affinity for LAG-3
PIERIS PHARMACEUTICALS GMBH1 citations59
US11168119B2Nov 9, 2021
Lipocalin muteins with binding affinity for LAG-3
PIERIS PHARMACEUTICALS GMBH1 citations59
US10947284B2Mar 16, 2021
Fusion molecules
PIERIS PHARMACEUTICALS GMBH1 citations59
US10927154B2Feb 23, 2021
Multi-specific polypeptide useful for localized tumor immunomodulation
PIERIS PHARMACEUTICALS GMBH1 citations58
US10787491B2Sep 29, 2020
Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (GPC3)
PIERIS PHARMACEUTICALS GMBH0 citations50
SANOFI SA
6 patentsUS9884898B2Feb 6, 2018
Proteins specific for pyoverdine and pyochelin
SANOFI SA17 citations92
US10329334B2Jun 25, 2019
Proteins specific for pyoverdine and pyochelin
SANOFI SA1 citations71
US10316071B2Jun 11, 2019
Fusion molecules
SANOFI SA2 citations70
US10118952B2Nov 6, 2018
Proteins specific for pyoverdine and pyochelin
SANOFI SA1 citations60
US10072056B2Sep 11, 2018
Proteins specific for pyoverdine and pyochelin
SANOFI SA1 citations60
US10065998B2Sep 4, 2018
Proteins specific for pyoverdine and pyochelin
SANOFI SA1 citations60